Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meth Watch: Manufacturing Propagation Mixed Across The U.S.

This article was originally published in The Tan Sheet

Executive Summary

Kansas provides a successful case study of the Meth Watch program's efficacy in reducing the manufacture of methamphetamine, according to Kansas Methamphetamine Prevention Project rep Cristi Cain

You may also be interested in...



Bill To Limit Pseudoephedrine Sale In Illinois Passes House, Moves To Senate

A bill limiting purchase of single-ingredient pseudoephedrine products in Illinois to two packages at a time is expected to pass the state Senate after unanimously clearing the House 114-0 May 25

Pseudoephedrine Tablets Go Behind The Counter In Oklahoma

Legislation restricting the sale of pseudoephedrine tablets to licensed pharmacies was signed into law in Oklahoma on April 7 and is being considered by other states looking to adopt similar measures

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel